ENBI Stock Overview
Operates as a biotechnology research and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Entheon Biomedical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.13 |
| 52 Week High | CA$0.25 |
| 52 Week Low | CA$0.05 |
| Beta | 1.05 |
| 11 Month Change | 0% |
| 3 Month Change | 44.44% |
| 1 Year Change | 30.00% |
| 33 Year Change | -97.40% |
| 5 Year Change | n/a |
| Change since IPO | -97.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENBI | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -3.7% | -8.9% | 1.3% |
| 1Y | 30.0% | -1.9% | 23.1% |
Return vs Industry: ENBI exceeded the Canadian Biotechs industry which returned 1.5% over the past year.
Return vs Market: ENBI exceeded the Canadian Market which returned 21.7% over the past year.
Price Volatility
| ENBI volatility | |
|---|---|
| ENBI Average Weekly Movement | 60.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: ENBI's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: ENBI's weekly volatility has decreased from 90% to 60% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1 | Timothy Ko | www.entheonbiomedical.com |
Entheon Biomedical Corp. operates as a biotechnology research and development company. It engages in developing of products for treating addiction and substance use disorders. The company is headquartered in Vancouver, Canada.
Entheon Biomedical Corp. Fundamentals Summary
| ENBI fundamental statistics | |
|---|---|
| Market cap | CA$1.15m |
| Earnings (TTM) | -CA$307.69k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs ENBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENBI income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$307.69k |
| Earnings | -CA$307.69k |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ENBI perform over the long term?
See historical performance and comparison